Who issues its first reports on tests and treatments for fungal infections

The World Health Organization (WHO) has published its first reports dealing with critical deficiency today medicines and Diagnostic tools For invasive fungal diseases, showing an urgent need for innovative research and development (R&D) to close these gaps.

Fungal diseases increasing care of public health, with usual infections – like Candida, which causes oral and vaginal jerks – it becomes more resistant to treatment. These infections disproportionately affect severely ill patients and those with a weakened immune system, including individuals who undergo cancer chemotherapy, live with HIV and who had organs transplants.

“Invasive fungal infections endanger lives of the most vulnerable, but the countries lack the treatment needed to save life,” said Dr. Yukiko Nakatani, who is Assistant General Director for Antimicrobial Resistance Temporary ad. “Not only is the pipeline of new antifungal drugs and diagnostics insufficient, there is a void in testing fungus in low and medium -sized countries, even in district hospitals. This diagnostic gap means that the cause of the suffering of people remains unknown, which makes it difficult for them to receive real treatment.”

Fungi in the top category 'Critical Priority' Who List of Pathogen Priority of Fungal Priority (FPPL) are deadly, with the mortality rates reach as much as 88%. Progress in treatments means that more people are likely to live with immune conditions, which could also mean an increase in cases of invasive fungal diseases. This is a complex challenge for managing due to the incompleteness of diagnostic tools, the limited availability of antifungal drugs and a slow and complex process of research and development for new treatments.

Limited process in the development of treatments against deadly fungal infections

Who is Antifungal drug report He points out that in the past decade, the regulatory bodies in the United States have approved only four new antifungal drugs. There are currently nine antifungal drugs in clinical development that would be used against the most vulnerable fungi that are threatening, as described in detail in FPPL.

However, only three candidates are in phase 3, the last phase of clinical development, which means that a little approval is expected in the next decade. Twenty -two drugs are in pre -clinical development, which is an insufficient number for the diet of clinical pipelines given the rates of abandonment, risks and challenges associated with the earlier stages of development.

Problems with current antifungal treatments include serious side effects, frequent drug interactions and drugs, limited dosage forms and need for long -term stay in the hospital. The report emphasizes the urgent need for safer antifungal drugs, perhaps reducing requirements for continuous drug monitoring.

Antifungal drugs that act against a wide range of severe infections caused by the pathogens of the priority of fungus are also required. Children are particularly insufficient with several clinical trials exploring pediatric dosage and formulations that correspond to age.

WHO recommends investing in global supervision, expanding financial incentives for drug detection and development, funding for basic research to identify new and unused goals of drug fungi and treatment of treatment that affect the immune reactions of patients.

Landscape Report on Diagnostics for Pathogenic Priority Fungus

New Diagnosis Report It shows that, although commercially available tests for the pathogenic priority of the fungus, they rely on well -equipped laboratories and dressed staff, which means that most people in low and medium income countries (LMIC) have no benefit to them. All countries, but especially LMIC, need faster, more precise, cheaper and easier testing of a wide range of mushroom pathogenic priority, including diagnostic tools that can be used in or near the point of care.

There are many challenges with existing antifungal diagnostics; They only work for a limited fungal range, they are not correct enough and they need to get results for a long time. Most tests are not well suitable for primary and secondary health care institutions, as certain diagnostics requires stable electricity supplies in appropriate and equipped laboratories.

Health workers often do not have sufficient knowledge of fungal infections, as well as the impact of fungi that become more resistant to treatments, resulting in a limited ability to perform the test necessary to determine appropriate treatment. WHO calls to strengthen the global response against invasive fungal diseases and antifungal resistance, and also develops a draft implementation for FPPL.